ArticleOncogene1999
Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor).
Article in Oncogene, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 345 citations in OpenAlex.
- Locally Aggressive Desmoid Tumor With L4-L5 Vertebral Invasion and Progressive Neurological Deficit: A Case Report.Clinical case reports · 2026Article
- CTNNB1 Mutational analysis enhances diagnostic precision in β-catenin-negative desmoid fibromatosis: a clinicopathological and molecular study.Virchows Archiv : an international journal of pathology · 2026Article
- Clinicopathological analysis of three cases of breast desmoid-type fibromatosis.BMC women's health · 2025Article
- Mesenteric Fibromatosis Presenting As Acute Abdominal Pain Mimicking a Perforated Viscus: A Case Report.Cureus · 2025Article
- Updates and controversies for desmoids in familial adenomatous polyposis.Familial cancer · 2025Review
- An intra-abdominal desmoid tumour: Case report.International journal of surgery case reports · 2025Article
- Paraspinal Desmoid Tumor in a Pediatric Patient with No Surgical History: A Case Report.Asian journal of neurosurgery · 2024Article
- Clinicopathological assessment of PD-1/PD-L1 immune checkpoint expression in desmoid tumors.European journal of histochemistry : EJH · 2023Article
- Molecular testing of soft tissue tumors.Diagnostic cytopathology · 2023Review
- TBL1X: At the crossroads of transcriptional and posttranscriptional regulation.Experimental hematology · 2022Review
- Molecular Pathogenesis of Sporadic Desmoid Tumours and Its Implications for Novel Therapies: A Systematised Narrative Review.Targeted oncology · 2022Review
- Centrosomal enrichment and proteasomal degradation of SYS-1/β-catenin requires the microtubule motor dynein.Molecular biology of the cell · 2022Article
- Expression of Beta-Catenin, Cadherins and P-Runx2 in Fibro-Osseous Lesions of the Jaw: Tissue Microarray Study.Biomolecules · 2022Article
- CRISPR-SID: Identifying EZH2 as a druggable target for desmoid tumors via in vivo dependency mapping.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Review
- Sporadic intra-abdominal desmoid tumor with a very unusual onset: two case reports.Journal of medical case reports · 2021Article
- Desmoplastic fibroma of the jaw bones: A series of twenty-two cases.Journal of bone oncology · 2021Article
- Soft Tissue Special Issue: Fibroblastic and Myofibroblastic Neoplasms of the Head and Neck.Head and neck pathology · 2020Review
- Novel pathogenic alterations in pediatric and adult desmoid-type fibromatosis - A systematic analysis of 204 cases.Scientific reports · 2020Article
- Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma.Journal of the National Cancer Institute · 2019Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aggressive fibromatosis (also called desmoid tumor) occurs as a sporadic lesion or as part of Familial Adenomatous Polyposis, which is caused by germ line mutations in the Adenomatous polyposis Coli (APC) gene. APC is involved in the regulation of the cellular level of beta-catenin, which is a mediator in Wnt signaling. Mutational analysis of the beta-catenin and APC genes was performed in 42 sporadic aggressive fibromatoses. Nine tumors had mutations in APC, and 22 had a point mutation in beta-catenin at either codon 45 or codon 41 (producing a stabilized beta-catenin protein product). Immunohistochemistry showed an elevated beta-catenin protein level in all tumors, regardless of mutational status. Beta-catenin localized to the nucleus, and was not tyrosine phosphorylated in the six tumors in which this was tested. The demonstration of mutations in two mediators in the Wnt-APC-beta-catenin pathway implicates beta-catenin stabilization as the key factor in the pathogenesis of aggressive fibromatosis. This is the first demonstration of somatic beta-catenin mutations in a locally invasive, but non metastatic lesion composed of spindle cells, illustrating the importance of beta-catenin stabilization in a variety of cell types and neoplastic processes. Moreover, this tumor has one of the highest reported frequencies of beta-catenin mutations of any tumor type.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.